Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. XTLB
  6. >
  7. Valuation
stocks logo

XTLB Valuation

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)

XTLB Relative Valuation

XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTLB is overvalued; if below, it's undervalued.

Historical Valuation

X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.03 is considered Undervalued compared with the five-year average of 10.21. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 214.44 to 218.52 according to relative valuation methord. Compared to the current price of 1.22 USD , X T L Biopharmaceuticals Ltd is Undervalued By 99.43%.
Relative Value
Fair Zone
214.44-218.52
Current Price:1.22
99.43%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
214.08
P/B
Median3y
275.67
Median5y
316.47
-15.44
FCF Yield
Median3y
-3.75
Median5y
-3.16

Competitors Valuation Multiple

The average P/S ratio for XTLB's competitors is 25.13, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.03, which is -99.87% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

People Also Watch

FAQ

arrow icon

Is X T L Biopharmaceuticals Ltd (XTLB) currently overvalued or undervalued?

X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.03 is considered Undervalued compared with the five-year average of 10.21. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 214.44 to 218.52 according to relative valuation methord. Compared to the current price of 1.22 USD , X T L Biopharmaceuticals Ltd is Undervalued By 99.43% .
arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB) fair value?

XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 214.44 to 218.52 according to relative valuation methord.
arrow icon

How does XTLB's valuation metrics compare to the industry average?

The average P/S ratio for XTLB's competitors is 25.13, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.03, which is -99.87% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
arrow icon

What is the current P/B ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?

As of Jul 08 2025, X T L Biopharmaceuticals Ltd (XTLB) has a P/B ratio of 214.08. This indicates that the market values XTLB at 214.08 times its book value.
arrow icon

What is the current FCF Yield for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?

As of Jul 08 2025, X T L Biopharmaceuticals Ltd (XTLB) has a FCF Yield of -15.44%. This means that for every dollar of X T L Biopharmaceuticals Ltd’s market capitalization, the company generates -15.44 cents in free cash flow.
arrow icon

What is the current Forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?

As of Jul 08 2025, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/E ratio of 2.64. This means the market is willing to pay $2.64 for every dollar of X T L Biopharmaceuticals Ltd’s expected earnings over the next 12 months.
arrow icon

What is the current Forward P/S ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?

As of Jul 08 2025, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/S ratio of 0.03. This means the market is valuing XTLB at $0.03 for every dollar of expected revenue over the next 12 months.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free